X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
afatinib (1028) 1028
oncology (630) 630
index medicus (618) 618
humans (519) 519
gefitinib (471) 471
erlotinib (390) 390
chemotherapy (380) 380
open-label (371) 371
mutation (353) 353
lung neoplasms - drug therapy (314) 314
female (265) 265
lung cancer (260) 260
adenocarcinoma (253) 253
1st-line treatment (250) 250
carcinoma, non-small-cell lung - drug therapy (240) 240
cancer (229) 229
lung cancer, non-small cell (210) 210
egfr (202) 202
male (202) 202
lung neoplasms - genetics (201) 201
epidermal growth factor (197) 197
acquired-resistance (191) 191
middle aged (185) 185
aged (173) 173
cell lung-cancer (172) 172
non-small cell lung cancer (169) 169
protein kinase inhibitors - therapeutic use (163) 163
tyrosine kinase inhibitors (161) 161
quinazolines - therapeutic use (157) 157
carcinoma, non-small-cell lung - genetics (154) 154
antineoplastic agents - therapeutic use (150) 150
nsclc (147) 147
tyrosine (147) 147
lung neoplasms - pathology (142) 142
growth-factor receptor (141) 141
epidermal growth factor receptor (136) 136
receptor, epidermal growth factor - genetics (136) 136
respiratory system (136) 136
tyrosine kinase inhibitor (136) 136
care and treatment (127) 127
respiratory tract diseases (125) 125
treatment outcome (120) 120
egfr mutations (117) 117
pharmacology & pharmacy (117) 117
erbb receptors - genetics (116) 116
genetic aspects (115) 115
adult (114) 114
carcinoma, non-small-cell lung - pathology (108) 108
mutations (108) 108
phase-iii (108) 108
tumors (107) 107
cancer therapies (106) 106
analysis (105) 105
quinazolines - pharmacology (105) 105
animals (104) 104
receptor, epidermal growth factor - antagonists & inhibitors (103) 103
patients (102) 102
protein kinase inhibitors - pharmacology (102) 102
multicenter (101) 101
cell line, tumor (100) 100
therapy (92) 92
aged, 80 and over (91) 91
epidermal growth factor receptors (91) 91
metastasis (91) 91
quinazolines - administration & dosage (90) 90
antineoplastic agents - pharmacology (89) 89
kinases (88) 88
resistance (88) 88
research (82) 82
egfr mutation (81) 81
non-small-cell lung cancer (80) 80
osimertinib (80) 80
antineoplastic combined chemotherapy protocols - therapeutic use (79) 79
bibw 2992 (79) 79
trial (79) 79
drug therapy (76) 76
health aspects (75) 75
adenocarcinoma - drug therapy (74) 74
non-small cell lung carcinoma (74) 74
quinazolines - adverse effects (74) 74
phase-ii trial (72) 72
clinical trials (70) 70
disease-free survival (70) 70
erbb receptors - antagonists & inhibitors (67) 67
neoplasms. tumors. oncology. including cancer and carcinogens (65) 65
protein-tyrosine kinase (64) 64
hematology, oncology and palliative medicine (63) 63
t790m (62) 62
erbb family blocker (61) 61
drug resistance, neoplasm (59) 59
inhibitors (59) 59
adenocarcinoma of lung (58) 58
lung-cancer (58) 58
medicine & public health (58) 58
mice (58) 58
original (57) 57
survival (56) 56
antineoplastic agents - adverse effects (55) 55
neoplasms (55) 55
prognosis (55) 55
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (1047) 1047
French (14) 14
Spanish (7) 7
German (6) 6
Chinese (5) 5
Korean (4) 4
Russian (4) 4
Czech (2) 2
Hungarian (2) 2
Japanese (2) 2
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


by Roos, M
ONCOLOGY RESEARCH AND TREATMENT, ISSN 2296-5270, 10/2017, Volume 40, Issue 10, pp. 639 - 639
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 03/2018, Volume 36, Issue 9, pp. 841 - 849
Purpose The AURA study (ClinicalTrials.gov identifier: NCT01802632) included two cohorts of treatment-naive patients to examine clinical activity and safety of... 
TYROSINE KINASE INHIBITORS | SURVIVAL | MULTICENTER | GEFITINIB | THERAPY | ONCOLOGY | ACQUIRED-RESISTANCE | OPEN-LABEL | AFATINIB | AZD9291 | ERLOTINIB
Journal Article
Journal of Thoracic Oncology, ISSN 1556-0864, 12/2018, Volume 13, Issue 12, pp. 1897 - 1905
Approximately 1% to 4% of NSCLC tumors harbor erb-b2 receptor tyrosine kinase 2 ( ) mutation; there is no approved targeted treatment for this subgroup.... 
Afatinib | NSCLC | ERBB2 mutation | BIBW 2992 | ADENOCARCINOMA | HER2 MUTATION | TRASTUZUMAB EMTANSINE | CHEMOTHERAPY | KINASE MUTATIONS | CELL LUNG-CANCER | PHASE-II TRIAL | THERAPY | CISPLATIN | ONCOLOGY | RESPIRATORY SYSTEM
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 08/2018, Volume 36, Issue 22, pp. 2244 - 2250
PurposeARCHER 1050, a randomized, open-label, phase III study of dacomitinib versus gefitinib in treatment-naive patients with advanced non-small-cell lung... 
1ST-LINE TREATMENT | CONTROLLED-TRIAL | MULTICENTER | ONCOLOGY | ADENOCARCINOMA | PHASE-3 TRIAL | OPEN-LABEL | AFATINIB | INHIBITOR | CHEMOTHERAPY | ERLOTINIB
Journal Article
Lung Cancer Management, ISSN 1758-1966, 12/2019, Volume 8, Issue 3, p. LMT15
Aim: The current study evaluated the efficacy and tolerability of second-line afatinib in patients with EGFR mutation-positive ( EGFRm+) non-small-cell lung... 
Journal Article
Medicina Clinica, ISSN 0025-7753, 04/2016, Volume 146, pp. 19 - 24
After description of the importance of EGFR mutations in non-small cell lung cancer and confirmation that tyrosine-kinase inhibitors are more beneficial than... 
Afatinib | Second-line | EGFR
Journal Article
Cancer Chemotherapy and Pharmacology, ISSN 0344-5704, 11/2018, Volume 82, Issue 5, pp. 757 - 766
Afatinib, an irreversible ErbB family blocker, has demonstrated preclinical antitumor activity with chemotherapy.As part of a phase I trial in patients with... 
Phase I | Medicine & Public Health | Afatinib | Paclitaxel | Carboplatin | Oncology | Cancer Research | Solid tumors | Pharmacology/Toxicology | BIBW 2992 | EGFR MUTATIONS | CHEMOTHERAPY | GEMCITABINE | CELL LUNG-CANCER | TRIAL | CISPLATIN | ONCOLOGY | PHARMACOLOGY & PHARMACY | ERBB FAMILY BLOCKER | ERLOTINIB | Afatinib - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Drug Administration Schedule | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - pharmacokinetics | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Carboplatin - administration & dosage | Paclitaxel - adverse effects | Male | Treatment Outcome | Carboplatin - pharmacokinetics | Paclitaxel - pharmacokinetics | Neoplasms - drug therapy | Carboplatin - adverse effects | Dose-Response Relationship, Drug | Maximum Tolerated Dose | Afatinib - pharmacokinetics | Female | Afatinib - adverse effects | Neoplasms - pathology | Paclitaxel - administration & dosage | Antimitotic agents | Complications and side effects | Care and treatment | Chemotherapy | Diarrhea | Clinical trials | Antineoplastic agents | Tumors | Cancer | Renal function | Toxicity | Exanthema | Dehydration | Hemorrhage | Small intestine | Anticancer properties | Safety engineering | Safety management | Drug dosages | Neutropenia | Mucositis | ErbB protein | Fatigue | Pharmacology | Patients | Stomatitis | Antitumor activity | Sepsis | Pharmacokinetics | Original
Journal Article
Clinical Cancer Research, ISSN 1078-0432, 12/2018, Volume 24, Issue 24, pp. 6548 - 6555
Purpose: EGFR exon 20 insertions account for up to 10% of all EGFR mutations in lung adenocarcinomas, representing the third most common cluster of mutations.... 
GROWTH-FACTOR RECEPTOR | MUTANTS | AFATINIB | ONCOLOGY | CANCER | AUY922
Journal Article
by Liu, YT and Li, Y and Ou, QX and Wu, X and Wang, XN and Shao, YW and Ying, JM
LUNG CANCER, ISSN 0169-5002, 04/2018, Volume 118, pp. 1 - 5
Objectives: Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are promising targeted therapies for EGFR-mutated non-small-cell lung... 
Resistance | Afatinib | NSCLC | ONCOLOGY | RESPIRATORY SYSTEM | Osimertinib | L718V | EGFR
Journal Article
Oncotarget, ISSN 1949-2553, 10/2018, Volume 9, Issue 78, pp. 34765 - 34771
Third-generation epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKIs) are markedly effective for T790M-positive patients. To confer their... 
Osimertinib | T790M | Afatinib | Rebiopsy | Bevacizumab
Journal Article
by Park, K
LANCET ONCOLOGY, ISSN 1470-2045, 07/2016, Volume 17, Issue 7, pp. E268 - E269
Journal Article
Acta histochemica, ISSN 0065-1281, 09/2019, Volume 121, Issue 8, p. 151439
Afatinib, a second-generation tyrosine kinase inhibitor, was designed to bind covalently to and irreversibly inhibit active ErbB family receptors. The major... 
Journal Article
Cancer Discovery, ISSN 2159-8274, 10/2012, Volume 2, Issue 10, pp. 922 - 933
EGFR-mutant lung cancers eventually become resistant to treatment with EGFR tyrosine kinase inhibitors (TKIs). The combination of EGFR-TKI afatinib and... 
lung cancer | EGFR tyrosine kinase inhibitors | afatinib | EGFR mutations | erlotinib | HER2 amplification | cetuximab | EGFR T790M | acquired resistance
Journal Article
ISSN 1758-1966, 12/2019, Volume 8, Issue 3
The current study evaluated the efficacy and tolerability of second-line afatinib in patients with mutation-positive ( m+) non-small-cell lung cancer (NSCLC)... 
afatinib | second line | EGFR
Journal Article
by Kim, Y and Lee, SH and Ahn, JS and Ahn, MJ and Park, K and Sun, JM
CANCER RESEARCH AND TREATMENT, ISSN 1598-2998, 04/2019, Volume 51, Issue 2, pp. 502 - 509
Journal Article
Bioanalysis, 09/2018, Volume 10, Issue 18, p. 1511
To support the therapeutic drug monitoring of afatinib (AFT), an ELISA was required. A hapten for AFT was prepared and linked to each of BSA and KLH proteins... 
Enzyme-Linked Immunosorbent Assay - methods | Animals | Rats | Afatinib - pharmacology | Drug Monitoring - methods | Afatinib - blood | Afatinib - therapeutic use
Journal Article
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, ISSN 1556-0864, 5/2017, Volume 12, Issue 5, pp. 884 - 889
Journal Article
No results were found for your search.

Cannot display more than 1000 results, please narrow the terms of your search.